|40. In adults with inflammatory bowel disease, we do not recommend any particular NSAID as the preferred choice to decrease the risk of worsening of inflammatory bowel disease symptoms.†|Very low|31|
|41. In adults with inflammatory bowel disease, we conditionally recommend treatment with TNFi monoclonal antibodies over treatment with other biologics.|Very low|32|
|42. We conditionally recommend the regular-interval use and monitoring of a validated AS disease activity measure.†|Very low|54|